First Patient Dosed in Japanese Prostate Cancer Imaging Study

Melbourne (Australia) and Kyoto (Japan) – 25 May 2021. Telix announces the first patient has been dosed in a clinical study in Japan using Telix’s investigational prostate cancer imaging product, Illuccix^®.

Telix is pleased to announce that the first patient has been dosed in a clinical study in Japan using Telix’s investigational prostate cancer imaging product TLX591-CDx (Illuccix^®, Kit for the preparation of ⁶⁸Ga-PSMA-11 injection). The study is an academic collaboration between Telix and Kanazawa University.

The study will enrol ten patients with advanced prostate cancer and is the first clinical evaluation of gallium-based PSMA imaging in Japan. The objective is to obtain safety data in a representative Japanese patient population, and to demonstrate that the targeting and biodistribution of TLX591-CDx in Japanese patients is consistent with international experience. Clinical data may facilitate development planning discussions with the PMDA and other Asian regulators.

Telix Japan President Dr. Shintaro Nishimura added, “This is the first study in Japan where a gallium based PSMA imaging agent is being systematically evaluated. Dosing the first patient represents a significant first step for the Japanese domestic medicine community to deliver innovative benefits to Japanese prostate cancer patients. We would like to express our appreciation to Dr. Inaki, the study’s principal investigator at Kanazawa University Hospital, the investigators and the study team for their excellent collaboration and, most importantly, the patients who will participate in this study.”

To read the full ASX disclosure please click here.

To return to the Telix homepage please click here.